Junior Information Technology Administrator

Paradromics gets FDA nod for broader BCI device compatibility. The FDA approval will enable the BCI platform to support more internet-connected personal devices including laptops, tablets and phones. Neurotech company Paradromics has received approval from the US Food and Drug Administration (FDA) to broaden the range of personal computing devices compatible with its investigational brain-computer interface (BCI) system. The authorisation pertains to the company's ongoing Connect-One Early Feasibility Study, which is evaluating the safety and functionality of the Connexus BCI for restoring communication and enabling computer-device control in individuals with severe motor impairment. The FDA approval will enable the BCI platform to support a wider variety of internet-connected personal devices including laptops, tablets and mobile phones. Paradromics intends to implement these changes through its Convey user interface, which is designed to translate decoded neural signals into communication and digital control across supported platforms. Previously, the BCI system was limited to use with company-provided hardware. The approval marks what Paradromics describes as a step towards allowing users with severe motor impairment to interact with the types of devices they use in everyday life. Once Paradromics completes the agreed deployment and testing process, new compatible personal devices could be added without requiring separate approvals for each device. The company stated that this change does not affect the existing clinical care model in the study but offers greater flexibility to assess how BCI-enabled computer control might fit into individual daily digital environments. Paradromics founder and CEO Matt Angle said: "As Medical Device Network think about building BCI as a technology platform, Medical Device Network need to push for generalised connectivity. "That means being able to connect with the products and technology that are already part of your life. This approval begins clearing the way toward a BCI platform that can move with the user rather than tethering him or her to a fixed computing environment." Paradromics is developing its BCI platform to decode neural activity recorded at the level of single neurons, with initial studies focused on restoring communication for people unable to speak due to paralysis and severe motor impairments. The company's stated long-term strategy aims to enable the translation of neural intent into actions across an expanding range of technologies and applications. In March this year, Paradromics initiated a programme to drive academia's access to its BCI to advance innovation in the device space. Give your business an edge with its leading industry insights.

Paradromics wins FDA nod to connect its BCI platform to personal devices. 2026-08-27 Brain-computer interface company Paradromics has secured a pivotal regulatory green light from the U.S. Food and Drug Administration to extend the compatibility of its BCI platform to personal devices, a move that signals a meaningful shift in how neural interface technology can be deployed and accessed in everyday settings. The clearance, confirmed this week, positions Paradromics as one of the first companies to receive explicit regulatory sanction for this class of device integration. What the FDA approval actually means. The FDA's decision to expand Paradromics' device compatibility framework is notable not simply as a business win but as a regulatory precedent. Until now, BCI systems approved for clinical use have largely operated within closed, proprietary hardware ecosystems - purpose-built devices that rarely communicate with the smartphones, tablets, or laptops that patients already own. By granting Paradromics the authority to interface its BCI with personal devices, the FDA is effectively acknowledging a new category of connected neural technology, one where the boundary between clinical hardware and consumer electronics is deliberately blurred. For regulatory affairs professionals across the industry, this approval will become a closely studied template for future submissions seeking similar connectivity permissions. The technology and its implications. Paradromics has long focused on high-bandwidth neural data acquisition, aiming to build systems capable of reading and transmitting neural signals with sufficient fidelity for practical communication and control applications. Extending that capability to personal devices introduces a new layer of practical utility: users could theoretically interact with their own phones or computers directly through their neural interface rather than through dedicated clinical terminals. This kind of ambient usability has been a long-standing goal in the BCI field, but regulatory hesitance around cybersecurity, data privacy, and device safety has historically kept it out of reach. The FDA clearance suggests that Paradromics has addressed enough of those concerns to satisfy regulators, though the specifics of any conditions or labeling requirements attached to the approval remain important details for the industry to monitor. Market context and the road ahead. This development arrives at a moment when the broader BCI sector is navigating intense scrutiny around long-term viability, safety, and real-world usability. Competitors including Synchron and Precision Neuroscience are pursuing their own connectivity and usability expansions, meaning Paradromics' regulatory win could accelerate a race toward personal-device integration across the field. For payers, hospital systems, and rehabilitation technology buyers, the ability to connect a BCI to existing personal hardware also carries meaningful cost implications, potentially reducing the infrastructure burden associated with deploying neural interface technology at scale. As the FDA's comfort with connected neural devices continues to evolve, Paradromics' clearance may well mark the opening of a new regulatory era in which the personal device becomes a standard component of the BCI ecosystem. Stay wired into neurotech BCI breakthroughs, funding rounds, and device clearances - weekly, free.